WordNet

the muscles of the abdomen (同)abdominal_muscle, ab
of or relating to or near the abdomen; "abdominal muscles"

PrepTutorEJDIC

(比較変化なし)腹の,腹部の

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. デスモイド腫瘍：疫学、危険因子、分子学的病因、臨床症状、診断、および局所療法 desmoid tumors epidemiology risk factors molecular pathogenesis clinical presentation diagnosis and local therapy
2. 血管内腹部大動脈修復術の合併症 complications of endovascular abdominal aortic repair
3. 腹部大動脈瘤の血管内修復 endovascular repair of abdominal aortic aneurysm
4. 肝障害の管理のための外科手技 surgical techniques for managing hepatic injury
5. 腹部大動脈瘤破裂の外科的および血管内修復 surgical and endovascular repair of ruptured abdominal aortic aneurysm

English Journal

A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis.

Jo JC1, Hong YS, Kim KP, Lee JL, Lee J, Park YS, Kim SY, Ryu JS, Lee JS, Kim TW.Author information 1Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, Korea.AbstractSeveral studies have reported that imatinib may induce tumor responses and prolonged disease stabilization in aggressive fibromatosis (AF). This effect may relate to the PDGFR-β pathway and KIT mutations. Sunitinib not only inhibits PDGFRs, KIT, and FLT3, it also blocks VEGFRs and thus serves as an antiangiogenic agent. The aim of this prospective multicenter uncontrolled study was to evaluate the efficacy and safety of sunitinib in patients with advanced AF. Nineteen patients with pathologically proven AF were recruited between June, 2008, and March, 2012, from three centers. One treatment cycle consisted of 37.5 mg/day sunitinib for 4 weeks without a break. The primary endpoint was tumor response rate according to RECIST 1.0. Ten (53 %) patients were female and the median age was 30 years (range, 22-67). Most of the primary sites were intra-abdominal (12, 63.2 %), and AF associated with familial adenomatous polyposis in ten patients (52.6 %). With a median of six cycles per patients (range, 1-47 cycles), five patients (26.3 %) achieved a partial response and eight (42.1 %) had stable disease. The overall response rate was 26.3 % (95 % confidence interval [CI], 6.3-45.7) in intention-to-treat analysis. With a median follow-up time of 20.3 months (range, 1.8-50.7), the 2-year rates of progression-free and overall survival were 74.7 % and 94.4 %, respectively. Grade 3 or 4 adverse events of sunitinib that occurred in >5 % of patients were neutropenia (33.3 %), diarrhea (5.3 %), and hand-foot syndrome (5.3 %). In 3 of 12 patients with mesenteric AF, mesenteric mass bleeding (n = 1), bowel perforation (n = 1), and bowel fistula (n = 1) with tumor mass necrosis were observed early during sunitinib treatment. Therefore, sunitinib showed potential antitumor activity and may be useful for the management of non-mesenteric AF.
Investigational new drugs.Invest New Drugs.2014 Apr;32(2):369-76. doi: 10.1007/s10637-013-0059-0. Epub 2014 Jan 16.
Several studies have reported that imatinib may induce tumor responses and prolonged disease stabilization in aggressive fibromatosis (AF). This effect may relate to the PDGFR-β pathway and KIT mutations. Sunitinib not only inhibits PDGFRs, KIT, and FLT3, it also blocks VEGFRs and thus serves as an
PMID 24425345

Surgical Outcomes following Resection for Sporadic Abdominal Wall Fibromatosis.

Wilkinson MJ1, Chan KE, Hayes AJ, Strauss DC.Author information 1Department of Academic Surgery, Sarcoma and Melanoma Unit, The Royal Marsden NHS Foundation Trust, London, UK.AbstractBACKGROUND: Fibromatosis can be classified according to site of origin, namely, extraabdominal, abdominal wall, or intraabdominal. This study reports on the surgical management and long-term outcomes from a single center in the management of sporadic abdominal wall fibromatosis.
Annals of surgical oncology.Ann Surg Oncol.2014 Mar 7. [Epub ahead of print]
BACKGROUND: Fibromatosis can be classified according to site of origin, namely, extraabdominal, abdominal wall, or intraabdominal. This study reports on the surgical management and long-term outcomes from a single center in the management of sporadic abdominal wall fibromatosis.METHODS: Patients who
PMID 24604586

Desmoid tumors do not prevent proctectomy following abdominal colectomy and ileorectal anastomosis in patients with familial adenomatous polyposis.

Church JM1, Xhaja X, Warrier SK, Laguardia L, O'Malley M, Burke C, Kalady MF.Author information 11Department of Colorectal Surgery, Cleveland Clinic, Cleveland, Ohio 2Sanford R Weiss, MD, Center for Hereditary Colorectal Neoplasia, Cleveland Clinic Foundation, Cleveland, Ohio 3Digestive Disease Institute, Cleveland Clinic Foundation, Cleveland, Ohio.AbstractBACKGROUND: Elective proctocolectomy has been recommended for patients at high risk of desmoids based on the possibility that cancer in a retained rectum may be unresectable because of desmoid disease. There are no data to support the reality of this concern.
Diseases of the colon and rectum.Dis Colon Rectum.2014 Mar;57(3):343-7. doi: 10.1097/DCR.0b013e3182a85d9f.
BACKGROUND: Elective proctocolectomy has been recommended for patients at high risk of desmoids based on the possibility that cancer in a retained rectum may be unresectable because of desmoid disease. There are no data to support the reality of this concern.OBJECTIVE: The aim of this study was to s
PMID 24509457